A Study Testing VX-407 in Patients with Autosomal Dominant Polycystic Kidney Disease Who Have Specific PKD1 Gene Changes

2 1 1

What is this study about?

Autosomal Dominant Polycystic Kidney Disease is a condition that runs in families where many fluid-filled sacs called cysts grow in the kidneys over time. These cysts can make the kidneys larger and may affect how well they work. This study is looking at a medication called VX-407 given as a tablet by mouth. The purpose of the study is to see if this treatment can help people with this kidney disease who have certain specific changes in a gene called PKD1. The study will also look at whether the medication is safe and how the body processes it.

During the study, participants will take VX-407 for up to 52 weeks. The main focus is to measure changes in the total size of the kidneys using a type of scan called MRI, which takes detailed pictures of the inside of the body. The study will check if the medication can slow down or stop the growth of the kidneys compared to the beginning of the study. Doctors will also watch for any side effects and will regularly check blood tests, heart tracings using a test called ECG, and other health measurements to make sure the medication is safe.

Before joining the study, participants will have a special genetic test done using a device that looks for specific changes in the PKD1 gene. This test uses a blood sample and looks for particular types of genetic changes that are not the kind that completely stop the gene from working. Only people with these specific genetic changes and who have kidneys of a certain size based on the MRI scan will be included in the study.

1 Initial assessment and confirmation

Upon joining the study, your eligibility will be confirmed. This includes verification that you are between 18 and 65 years of age and have a body mass index (a measure of body fat based on height and weight) between 18 and 45 kg/m².

Your diagnosis of autosomal dominant polycystic kidney disease (a genetic condition causing fluid-filled sacs called cysts to grow in the kidneys) will be verified through existing medical records and imaging results.

An abdominal MRI scan (a type of imaging that uses magnetic fields to create detailed pictures of internal organs) will be performed to measure your total kidney volume and confirm your classification status.

Your kidney function will be assessed through blood tests to ensure your estimated glomerular filtration rate (a measure of how well your kidneys filter waste from blood) is at least 25 ml/min/1.73 m².

A genetic test using a designated study assay will confirm that you have a specific type of gene variant in the PKD1 gene (the gene associated with your condition) that qualifies you for this study.

2 Treatment period with VX-407

You will receive VX-407, which is provided as a tablet to be taken by mouth.

The study will monitor how the medication affects your kidney cyst growth over time.

Regular blood samples will be collected to measure the levels of VX-407 in your bloodstream and to assess how your body processes the medication.

3 Ongoing monitoring and assessments

Throughout the study, repeated MRI scans will be performed to measure changes in your total kidney volume compared to the initial measurement.

Regular safety assessments will be conducted, including monitoring for any adverse events (unwanted or harmful effects that may occur during treatment).

Blood tests will be performed regularly to check your blood cell counts, kidney and liver function, and blood clotting ability.

Electrocardiograms (tests that measure the electrical activity of your heart, abbreviated as ECGs) will be performed using a standard 12-lead setup.

Your vital signs (measurements such as blood pressure, heart rate, and temperature) will be monitored at scheduled visits.

4 Study completion

The study is expected to continue until approximately August 2027.

Final assessments will include measurement of kidney volume changes, safety evaluations, and collection of information about how the medication worked in your body.

Who Can Join the Study?

You must be between 18 and 65 years old at the time of signing the consent form for the screening period
Your body mass index (a measure of body fat based on height and weight) must be between 18 and 45 kg/m2
You must have a confirmed diagnosis of Autosomal Dominant Polycystic Kidney Disease (a genetic condition where fluid-filled sacs called cysts grow in the kidneys), which can be shown by:
- Having evidence that one or both of your biological parents have polycystic kidney disease AND having a certain number of cysts in your kidneys based on your age: at least 3 cysts total in both kidneys if you are younger than 40 years old, at least 2 cysts in each kidney if you are between 40 and 59 years old, or at least 4 cysts in each kidney if you are 60 years old or older
- OR if you do not have a family history of this disease: having at least 10 cysts in each kidney
You must have a specific Mayo imaging classification status (a system that measures kidney size and disease progression) of 1B with a kidney volume of at least 250 mL/m, or 1C, 1D, or 1E, confirmed by an MRI scan (a type of imaging test) of your abdomen done during the screening period
You must have a specific type of genetic variant (a change in your genes) in the PKD1 gene that is disease-causing, likely disease-causing, or uncertain, but not a type that stops the gene from working completely. This must be confirmed by a special genetic test
Your estimated kidney function (a measure of how well your kidneys filter waste from your blood) must be at least 25 mL/min/1.73 m2 based on a specific calculation method

Who Cannot Join the Study?

No specific exclusion criteria have been provided for this clinical trial at this time

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
Hopital Necker Enfants Malades	Paris	France
Centre Hospitalier Regional Et Universitaire De Brest	Brest	France
Katholieke Universiteit te Leuven	Leuven	Belgium

Other Sites

Site Name	City	Country
Fundacio Puigvert	Barcelona	Spain
Charite Universitaetsmedizin Berlin KöR	Berlin	Germany
Hospital Universitario Fundacion Jimenez Diaz	Madrid	Spain
Cbrebyrsc Upcgomegacuxya Snfutvboq	Woluwe-Saint-Lambert	Belgium
Ueetqpoobdwj Mzpqakk Czzvnbp Gldyprppl	Groningen	The Netherlands
Uiilfptkjr Homxhbud Cjbtxku	Cologne	Germany
Euiofmm Uuzyydbmokob Mnhcwtv Cbyvazj Rgbvmsivv (kaqbkcb Mwz	Rotterdam	The Netherlands
Cqqekx Hsbilytzhiq Rlivkusc Uzjamkloqlmln Dk Tgaox	Tours	France

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	20.12.2025
France	Recruiting	20.12.2025
Germany	Recruiting	20.12.2025
Italy	Not yet recruiting	20.12.2025
Spain	Recruiting	20.12.2025
The Netherlands	Recruiting	20.12.2025

Trial locations

Investigated drugs:

VX-407

VX-407 is an investigational medication being studied for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This is a genetic condition where fluid-filled cysts grow in the kidneys and can cause them to lose function over time. VX-407 is being tested specifically in patients who have certain variants in a gene called PKD1, which is responsible for causing this form of kidney disease. The medication is designed to help slow down or stop the progression of the disease.

Autosomal Dominant Polycystic Kidney Disease – Autosomal Dominant Polycystic Kidney Disease is a genetic disorder that affects the kidneys and is passed down through families. The condition causes numerous fluid-filled sacs called cysts to develop in both kidneys over time. These cysts gradually grow larger and increase in number as a person ages. As the cysts expand, they replace normal kidney tissue and cause the kidneys to enlarge significantly. The growing cysts interfere with the kidneys’ ability to filter waste products from the blood and maintain proper fluid balance in the body. Over many years, the progressive enlargement and multiplication of cysts leads to reduced kidney function.

Trial ID:

2024-517393-13-00

Protocol code:

VX24-407-101

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Study Testing VX-407 in Patients with Autosomal Dominant Polycystic Kidney Disease Who Have Specific PKD1 Gene Changes

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?